Robert Driscoll
Stock Analyst at Wedbush
(1.98)
# 2,988
Out of 4,761 analysts
156
Total ratings
32.14%
Success rate
-5.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Maintains: Outperform | $34 → $36 | $8.25 | +336.36% | 8 | Feb 6, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $52 | $21.85 | +137.99% | 9 | Dec 17, 2024 | |
| RVMD Revolution Medicines | Maintains: Outperform | $70 → $67 | $41.34 | +62.07% | 4 | Dec 6, 2024 | |
| TYRA Tyra Biosciences | Reiterates: Outperform | $28 | $13.17 | +112.60% | 8 | Oct 25, 2024 | |
| BDTX Black Diamond Therapeutics | Reiterates: Outperform | $16 | $2.16 | +640.74% | 10 | Oct 8, 2024 | |
| RCUS Arcus Biosciences | Reiterates: Outperform | $30 | $11.07 | +171.00% | 7 | Oct 3, 2024 | |
| IGMS IGM Biosciences | Maintains: Outperform | $25 → $22 | $1.38 | +1,494.20% | 10 | Oct 1, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $85 → $51 | $8.18 | +523.47% | 1 | Sep 20, 2024 | |
| ACET Adicet Bio | Reiterates: Outperform | $5 | $0.97 | +413.66% | 8 | Sep 20, 2024 | |
| CGEM Cullinan Therapeutics | Reiterates: Outperform | $36 | $9.03 | +298.67% | 4 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $6.22 | +76.85% | 3 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $2.62 | +319.85% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $4 | $2.32 | +72.41% | 9 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $5.23 | +148.57% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $2.36 | +450.85% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $36.01 | +105.50% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $0.16 | +7,404.69% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $2.92 | +173.97% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $17.77 | +220.77% | 8 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $2.57 | +172.37% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $8 | $0.78 | +925.64% | 9 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $0.61 | +1,217.09% | 7 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $52 | $13.98 | +271.96% | 5 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $35 | $12.43 | +181.58% | 5 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $1.38 | +552.17% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $4 | $3.42 | +16.96% | 4 | May 19, 2020 |
Kura Oncology
Feb 6, 2025
Maintains: Outperform
Price Target: $34 → $36
Current: $8.25
Upside: +336.36%
IDEAYA Biosciences
Dec 17, 2024
Reiterates: Outperform
Price Target: $52
Current: $21.85
Upside: +137.99%
Revolution Medicines
Dec 6, 2024
Maintains: Outperform
Price Target: $70 → $67
Current: $41.34
Upside: +62.07%
Tyra Biosciences
Oct 25, 2024
Reiterates: Outperform
Price Target: $28
Current: $13.17
Upside: +112.60%
Black Diamond Therapeutics
Oct 8, 2024
Reiterates: Outperform
Price Target: $16
Current: $2.16
Upside: +640.74%
Arcus Biosciences
Oct 3, 2024
Reiterates: Outperform
Price Target: $30
Current: $11.07
Upside: +171.00%
IGM Biosciences
Oct 1, 2024
Maintains: Outperform
Price Target: $25 → $22
Current: $1.38
Upside: +1,494.20%
Corbus Pharmaceuticals Holdings
Sep 20, 2024
Maintains: Outperform
Price Target: $85 → $51
Current: $8.18
Upside: +523.47%
Adicet Bio
Sep 20, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.97
Upside: +413.66%
Cullinan Therapeutics
Sep 18, 2024
Reiterates: Outperform
Price Target: $36
Current: $9.03
Upside: +298.67%
Sep 12, 2024
Reiterates: Outperform
Price Target: $11
Current: $6.22
Upside: +76.85%
Aug 13, 2024
Reiterates: Outperform
Price Target: $11
Current: $2.62
Upside: +319.85%
Aug 12, 2024
Upgrades: Neutral
Price Target: $4
Current: $2.32
Upside: +72.41%
Aug 9, 2024
Reiterates: Outperform
Price Target: $13
Current: $5.23
Upside: +148.57%
Aug 8, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $2.36
Upside: +450.85%
Aug 8, 2024
Reiterates: Outperform
Price Target: $74
Current: $36.01
Upside: +105.50%
Aug 7, 2024
Reiterates: Outperform
Price Target: $12
Current: $0.16
Upside: +7,404.69%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $2.92
Upside: +173.97%
Jul 31, 2024
Reiterates: Outperform
Price Target: $57
Current: $17.77
Upside: +220.77%
Jun 7, 2024
Reiterates: Outperform
Price Target: $7
Current: $2.57
Upside: +172.37%
May 9, 2024
Upgrades: Outperform
Price Target: $3 → $8
Current: $0.78
Upside: +925.64%
May 3, 2024
Reiterates: Outperform
Price Target: $8
Current: $0.61
Upside: +1,217.09%
Nov 8, 2023
Reiterates: Outperform
Price Target: $52
Current: $13.98
Upside: +271.96%
Nov 7, 2023
Maintains: Outperform
Price Target: $39 → $35
Current: $12.43
Upside: +181.58%
Aug 24, 2023
Initiates: Outperform
Price Target: $9
Current: $1.38
Upside: +552.17%
May 19, 2020
Upgrades: Outperform
Price Target: $2 → $4
Current: $3.42
Upside: +16.96%